Bilthoven Biologicals
Bilthoven Biologicals produces various products such as polio, diphtheria tetanus polio combination vaccine (DT-IPV), tetanus vaccines and BCG for the treatment of bladder cancer. At BBio we are working on developing vaccines that give our world population a chance for a life without disease. We deliver on our promise: to make vaccines for a better world. We do this together with our partners. For everyone. Worldwide. And we do that well.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
The opportunities we get in life, determine who we become. BBio will fight to prevent threatening diseases to get in the way of these opportunities.
Therefore, our team of responsible and motivated experts work around the clock, producing vaccines to give the world’s population a chance to reach their full potential in a life without disease.
We deliver on our promise to make vaccines for a better world. We do this together with our partners. For everyone. All over the world.
And we do this right.
Vision and commitment
We produce high quality vaccines in a state of the art production environment to meet global demand.
This way we take responsibility in the fight to eliminate life threatening diseases!
We actively participate in the polio eradication programme and prevention and treatment of life threatening diseases by delivering affordable, high quality products.
We provide anyone, every child an equal opportunity for a healthy start in life.
See what we produce
How it started
Bilthoven Biologicals emerged after privatizing NVI, formerly part of RIVM. The Cyrus Poonawalla Group acquired the vaccine producing part of NVI in 2012 and founded Bilthoven Biologicals.
Our history
We originated from the National Institute for Public Health and the Environment (RIVM). Here the development and production of vaccines started. In 2003, the activities for the national vaccination programme were continued under the name Dutch Vaccine Institute (NVI). An estimated 30% of vaccines produced globally are made with technology developed in Bilthoven.
Cyrus Poonawalla Group
Bilthoven Biologicals (BBio) originated after privatizing NVI. The Cyrus Poonawalla Group acquired the vaccine producing part of NVI and founded BBio. This resulted in a powerful combination of knowledge, network and facilities we employ daily to achieve our ambitions.
Dr. Cyrus Poonawalla is CEO of the Cyrus Poonawalla group. He built Serum Institute of India, a successful vaccine conglomerate which is the world’s largest vaccine producer in sheer volume. He learned his trade at USPB, then called Antonie van Leeuwenhoek site.
In the 1970’s, the Dutch government took part in an exchange programme, inviting students from developing nations to learn how to develop vaccines. This way, we achieved using this knowledge by developing nations.
Dr. Poonawalla made his company Serum Institute of India (SII) into a vaccine conglomerate. He bought the production part of the Dutch Vaccine Institute (NVI) in 2012, resulting in Bilhoven Biologicals. The acquisition of BBio resulted in a massive increase in production of polio vaccines. This contributes greatly to the effort to eradicate polio globally!